UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 12, 2006
DYNAVAX TECHNOLOGIES CORPORATION
(Exact name of registrant as specified in charter)
| |
|
|
|
|
| Delaware
|
|
000-50577
|
|
33-0728374 |
| (State or other
jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.) |
2929 Seventh Street, Suite 100
Berkeley, California 94710
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (510) 848-5100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| |
TABLE OF CONTENTS
Item 8.01. Other Events.
In a press release dated November 12, 2006, the Company announced additional data from a Phase
2b study involving its TOLAMBA™ investigational therapy.
The press release dated November 12, 2006, titled “Dynavax Reports New TOLAMBA Data at ACAAI
Meeting,” is attached hereto as Exhibit 99.1 and is herein incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
99.1
|
|
Press Release, dated November 12, 2006, entitled “Dynavax
Reports New TOLAMBA Data at ACAAI Meeting.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| |
|
|
|
|
| |
Dynavax Technologies Corporation
|
|
| Dated: November 13, 2006 |
By: |
/s/ Deborah A. Smeltzer
|
|
| |
|
Deborah A. Smeltzer, Vice President, |
|
| |
|
Operations and Chief Financial Officer |
|